Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Safety Shot Announces First Peer-Reviewed Publication of Human Clinical Trial Confirming Rapid Alcohol Reduction and Hangover Prevention

In This Article:

Safety Shot, Inc.
Safety Shot, Inc.

New controlled study published in Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake

SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot® in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot® statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p < 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: https://doi.org/10.2147/NDS.S507571

"This is a momentous occasion for Safety Shot as it demonstrates in a peer-reviewed setting, the potential for the product’s utility in daily practice. Alcohol consumption may have implications in multiple settings, but the results of this study show that there are solutions available – over the counter – that can mitigate its effects and dangers and allow for a more positive overall experience," said Jarrett Boon, Safety Shot CEO. "Our unwavering commitment to scientific research and development has culminated in this groundbreaking achievement, and we believe that this clinically proven solution empowers individuals to take responsibility and control of their alcohol consumption."

This is the first-ever human clinical trial to demonstrate the efficacy of a dietary supplement blend in reducing the acute effects of alcohol. Previous research has primarily relied on animal models, which may not translate directly into human physiology. Safety Shot's human clinical trial provides more relevant and reliable data, positioning Safety Shot® as a revolutionary advancement in the field and a potential game-changer for the growing market of individuals seeking to manage the after-effects of alcohol consumption.

Details of the Trial

The study, conducted by The Center for Applied Health Sciences (CAHS), an independent, third-party research organization, involved healthy men and women of various ages, ethnicities and body types. Participants were randomly assigned to consume alcohol followed by either Safety Shot® or a placebo in a crossover design, where each participant served as their own control. This rigorous double-blind, randomized, placebo-controlled, crossover design ensured the highest level of scientific rigor and minimized inter-individual variability. Details include: